London-based LIfT BioSciences secures €12 million to ovecome treatment resistance in solid tumours
London-based LIfT BioSciences secures €12 million to ovecome treatment resistance in solid tumours LIfT BioSciences, a British/Irish BioTech focused on neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment
